NEW YORK (GenomeWeb) – Invitae has commenced an underwritten public offering of $40 million worth of shares of its common stock, the company said yesterday.

All shares of common stock are offered by Invitae before deducting underwriting discounts, commissions or other expenses. JP Morgan Securities is the book-running manager for the offering.

Invitae said it will offer the underwriter a 30-day option to buy an as much as $6 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.